Effective Feb. 2, 2023, AMA Initial and Reappointment Profiles have been updated to reflect significant changes.
Additional Program Completion Information in Initial Profiles
In the Initial Profile, dates displayed in the ACGME-accredited graduate medical training programs section have been enhanced to include more finite information. Previously, only month and year were displayed to reflect program dates. With the change, those dates are now shown in month, day, and year format.
Removal of DEA DATA Waiver Code-Subcode Combinations on Reappointment Profiles
The DEA section of both Initial and Reappointment Profiles has been revised to remove mention of code-subcode combinations that indicated the presence of a DEA DATA Waiver.
In Jan. 2023, the DEA announced that it was sunsetting DATA-Waiver Program in compliance with the Consolidated Appropriations Act of 2023. Per the announcement, eliminating this program will make buprenorphine for opioid use disorder readily and safely available to anyone who needs it.
As a result of this change:
- Physicians are no longer required to have a DATA-Waiver registration to treat patients with buprenorphine for opioid use disorder.
- All prescriptions for buprenorphine will only require a standard DEA registration number and not a DATA-Waiver registration number.
- Limits and patient caps per prescriber related to treating opioid use disorder with buprenorphine have also been eliminated.
- The Act does not impact existing state laws or regulations that may be applicable.
- New training requirements have been identified for all prescribers, which will not go into effect until Jun. 21, 2023.
This enhancement and revision apply to newly purchased AMA Profiles, as well as those previously purchased profiles that may be updated via AMA’s Continuous Monitoring Service after that date.
To learn more, please read the DEA’s letter to registrants or visit the Substance Abuse and Mental Health Services Administration site.